Revised forecast
Fiscal year ending September 2026 · Full yearPrevious forecast published 13 November 2025The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
Measures to improve profitability have progressed smoothly as a result of reviewing the business portfolio and concentrating management resources in highly profitable areas, while business synergies from strengthened collaboration with ＳＢＣメディカルグループ株式会社 also contributed. As a result of the shift toward highly profitable areas and progress in measures to improve profit margins, the operating profit margin is expected to rise from 12.9% in the previous forecast to 16.0%.
| Item | Details |
|---|---|
| Net Sales | ¥2,345 million → ¥2,500 million（+6.6%） |
| Operating profit | ¥304 million → ¥400 million（+31.6%） |
| Ordinary income | ¥294 million → ¥390 million（+32.7%） |
| Profit attributable to owners of the parent | ¥184 million → ¥250 million（+35.9%） |
| Net income per share | 52.44 yen and sen → 68.62 yen and sen |
| Fiscal Period Covered | Fiscal year ending September 2026 |
| Period Covered | Full year |
| Publication date of previous forecast | 13 November 2025 |
| Previous-period results | Net sales ¥1,960 million, operating profit ¥150 million, ordinary profit ¥152 million, profit attributable to owners of the parent ¥44 million, and earnings per share ¥12.32 (fiscal year ended September 2025) |
| Reason for the revision | Measures to improve profitability have progressed smoothly as a result of reviewing the business portfolio and concentrating management resources in highly profitable areas, while business synergies from strengthened collaboration with ＳＢＣメディカルグループ株式会社 also contributed. As a result of the shift toward highly profitable areas and progress in measures to improve profit margins, the operating profit margin is expected to rise from 12.9% in the previous forecast to 16.0%. |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (2)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Measures to improve profitability have progressed as a result of reviewing the business portfolio and concentrating management resources in highly profitable areas. Business synergies from strengthened collaboration with the parent company, ＳＢＣメディカルグループ株式会社, also contributed.